Worldwide Healthcare Trust Plc (LSE:WWH) offers investors access to a global portfolio of healthcare companies, including pharmaceutical groups, biotechnology firms, medical technology businesses and healthcare services providers. The shares rose by 0.79% on 26 October 2026 to GBX 385.0, a gain of GBX 3.00. …
IXICO Plc (LSE:IXI) is a small neuroscience company that helps drug developers measure how brain diseases progress by analysing medical images taken during clinical trials. Its shares are traded on AIM, the London market for smaller growing companies, where large percentage moves can occur …
Smith & Nephew Plc (LSE:SN.) develops and sells medical devices used in joint replacement, arthroscopic and ear, nose and throat procedures, and in the treatment of chronic and acute wounds. The shares eased by 1.17% on 26 October 2026. A one-day move of this …
CVS Group plc is in focus for investors assessing UK-listed shares on 26 October 2026, with attention centred on veterinary services. The company’s market narrative is shaped by like-for-like growth, vet recruitment and retention, pricing, client demand, margins and competition. Rather than relying on …
Aptamer Group PLC — LSE:APTA closed 3.17% higher on26 October 2026, with the shares at 0.325p after an increase of 0.01p on the day.
Cambridge Cognition Holdings PLC — LSE:COG closed 3.70% higher on26 October 2026, with the shares at 28.00p after an increase of 1.00p on the day.
Polar Capital Global Healthcare Trust Plc (LSE:PCGH) gives investors access to a managed portfolio of healthcare companies from around the world, ranging from large pharmaceutical groups to smaller medical technology and biotechnology businesses. The shares rose by 1.13% on 26 October 2026 to GBX …
Oxford Biomedica Plc (LSE:OXB) provides development and manufacturing services for companies that are creating cell and gene therapies, including viral vector production that underpins many of these treatments. The shares rose by 2.72% on 26 October 2026 to GBX 528.0, a gain of GBX …
Late-October disclosures included new lung- and bladder-cancer trial results and US accelerated approval for a renal treatment. The oncology congress also brought pivotal survival-data presentations. These developments broaden the clinical narrative, but trial outcomes, regulatory labels and commercial availability are separate stages; an investigational …
The half-year statement described delivery in line with the annual and medium-term framework and confirmed guidance. It distinguished underlying growth measures from specific product-related effects. Investors should assess the performance of the core care categories, manufacturing execution and access rather than interpreting a modest …